Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | CTSK | P43235 | 2/20 | 0.37 |
| ▸ | F2 | P00734 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1139547 | 0.89 | CTSS (0.53) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL1139393 | 0.87 | CTSS (0.50) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL1139151 | 0.87 | CTSS (0.54) | CTSSCTSLCTSBCTSK | |
| SCHEMBL1137915 | 0.83 | CTSS (0.36) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL1139788 | 0.83 | CTSS (0.42) | CTSSCTSLCTSBCTSKF2 | |
| SCHEMBL1139100 | 0.82 | CTSS (0.39) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL1139054 | 0.82 | CTSS (0.43) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL1138672 | 0.81 | CTSS (0.40) | CTSSCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL1139367 | 0.79 | CTSS (0.36) | CTSSCTSLCTSBCTSKNPC1 | |
| SCHEMBL1138994 | 0.78 | CTSS (0.48) | CTSSCTSLCTSBCTSKALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | claimed |
| EP-2440521-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | claimed |
| US-7893099-B2 | Cyclopentane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-02-22 | — | — | US | claimed |
| WO-2010142650-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | claimed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | claimed |
| EP-2440521-B1 | NOVEL CYCLOPENTANE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-04-30 | — | — | EP | disclosed |
| EP-2440521-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-7893099-B2 | Cyclopentane derivatives | HOFFMAN-LA ROCHE INC. (US) | 2011-02-22 | — | — | US | disclosed |
| WO-2010142650-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | WO | disclosed |
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317647-A1 | NOVEL CYCLOPENTANE DERIVATIVES | TBXA2R, ADORA1, CNR1 | CTSS 2367/4885CTSL 2122/4885CTSB 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.